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Changes in White Matter Microstructure Suggest
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Objective. To assess white matter (WM) and gray
matter (GM) magnetization transfer ratio histogram
peak heights (MTR-HPHs) in different subsets of
patients with neuropsychiatric systemic lupus erythe-
matosus (NPSLE) who have unremarkable findings on
3T magnetic resonance imaging of the brain and to
evaluate whether these values could be used to highlight
different clinically suspected underlying pathogenic
processes or identify the clinical NPSLE status or
whether they could be associated with a specific NPSLE
syndrome.
Methods. Sixty-four SLE patients with neuropsy-
chiatric symptoms were included. The initial NPSLE
diagnosis and suspected underlying pathogenic process
were established by multidisciplinary evaluation. The
final diagnosis was made after also considering the dis-
ease course 6–18 months later. Thirty-three patients
with central nervous system (CNS) NPSLE and 31 SLE
patients with neuropsychiatric symptoms unrelated to
SLE (non–SLE-related NP) were included. Twenty SLE
patients without neuropsychiatric symptoms and 36
healthy control subjects were included for comparison.
Differences in the WM and GM mean MTR-HPHs and
between the different NPSLE subgroups (CNS NPSLE
diagnosis, NPSLE phenotype [inflammatory or ische-
mic], and clinical changes after treatment) and the
relationship to NPSLE syndromes were evaluated.
Results. Patients with inflammatory NPSLE had
significantly lower WM MTR-HPHs than did the
healthy controls, the SLE patients, and the non–SLE-
related NP patients. Cognitive disorder, mood disorder,
and psychosis were related to lower WM MTR-HPH
values and cerebrovascular symptoms to higher values.
Furthermore, the mean MTR-HPHs in the WM
increased when the clinical status of the NPSLE
patients improved.
Conclusion. Measurement of MTR-HPH of the
WM has the potential to identify inflammatory NPSLE
with CNS involvement. This finding underscores the
usefulness of this technique for the detection of cerebral
changes in NPSLE patients and for the assessment of
clinical changes after treatment.
Systemic lupus erythematosus (SLE) is an auto-
immune disease characterized by acute or chronic
inflammation of multiple organs (1). Nervous system
involvement in SLE, which is referred to as neuropsy-
chiatric SLE (NPSLE), leads to a broad, nonspecific,
and heterogeneous group of NP manifestations (1,2). In
1999, the American College of Rheumatology (ACR)
published a consensus document describing the diagnos-
tic and exclusion criteria for 19 NPSLE syndromes (3).
Although widely used, its effectiveness is limited and
NPSLE remains a diagnosis per exclusion. Thus, in clini-
cal practice, clinical suspicion of a certain pathogenic
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process underlying the clinical symptoms drives the ther-
apeutic choice in these patients (4–6).
Two main underlying pathophysiologic processes
have been described in NPSLE, based on pathologic
changes in humans and on findings in animal models.
The inflammatory process (inflammatory NPSLE) has
been associated with dysfunction due to pathogenic anti-
bodies and a disrupted blood–brain barrier, while the
thrombotic process (ischemic NPSLE) has been associat-
ed with focal neurologic deficits that can be attributed to
interruption of blood flow in a specific brain region
(5–7). Consistent with the suspected mechanism, therapy
will be directed at the inflammation, with the use of
immunosuppressive medications, or at the ischemia,
with the use of antiaggregant and/or anticoagulant medi-
cations. These two phenotypes can also coexist.
So far, both the characterization of a certain
NPSLE phenotype and the correct attribution of NP
events to SLE or to an alternative cause remain a chal-
lenge (8). None of the diagnostic tests currently used in
clinical practice is specific for any NPSLE manifestation
or phenotype. Although magnetic resonance imaging
(MRI) is the neuroimaging technique of choice in
NPSLE, this technique yields unremarkable findings in
a significant proportion of patients, independently of
the NPSLE syndrome and its severity (8,9). There is
thus an imperative need for radiologic techniques that
help in the diagnostic process of NPSLE and in the
identification of NPSLE phenotypes (2).
Magnetization transfer imaging (MTI) is a quan-
titative MRI technique known to be useful in the detec-
tion of cerebral abnormalities in brain tissue that looks
normal on conventional MRI. This technique is based
on the application of off-resonance radiofrequency
pulses. Measurement of signal intensity with and with-
out the application of these pulses allows the calculation
of an index called the magnetization transfer ratio
(MTR), which indirectly reflects the integrity of macro-
molecular structures (e.g., myelin) that exchange mag-
netization with the surrounding water (10,11). Among
all of the MTI parameters, the histogram peak height
(HPH), or the proportion of brain pixels at the most
common MTR value, is the most informative parameter
in NPSLE without explanatory MRI findings. These val-
ues have been used as a quantitative estimate of tissue
microstructural integrity in NPSLE (12,13).
In preliminary investigations, Bosma and co-
workers (14,15) observed a significantly lower whole-
brain MTR-HPH in both active and past NPSLE when
compared with healthy controls. Those authors found
an association between MTR-HPH and neurocognitive
impairment and suggested that neuronal dysfunction
may underlie central nervous system (CNS) involvement
in NPSLE (16). It has also been demonstrated that SLE
patients with a history of NP had markedly lower gray
matter (GM) MTR-HPHs than did healthy controls
(17). Emmer and coworkers (18) showed how decreased
whole-brain MTR-HPHs in patients with active NPSLE
increased when the clinical status improved, underscor-
ing the possible partial reversibility of the previously
observed abnormalities. Those authors also showed that
in NPSLE, there is a relationship between MTR-HPHs
and neuronal impairment, as revealed by other quantita-
tive neuroimaging techniques, such as diffusion-
weighted imaging and proton magnetic resonance spec-
troscopy (13,19).
Despite these promising data, MTI has been
applied only in a limited number of patients. The above-
mentioned findings have never been reproduced in a
NPSLE cohort assessed through a multidisciplinary
approach and followed prospectively. Prospective follow-
up is essential for a diagnosis of NPSLE. In the acute clin-
ical setting, recognizing the cause of NPSLE can be diffi-
cult, whereas at follow-up, the diagnosis can be assessed
more reliably since the clinical course and response or
failure to treatment provide diagnostic information.
The purposes of our study were to assess white
matter (WM) and GM MTR-HPHs in a well-defined,
prospectively followed cohort of SLE patients with NP
symptoms that were either related or unrelated to SLE,
to investigate whether these parameters may highlight
different pathogenic NPSLE processes (inflammatory
or ischemic), and to reproduce previous findings pub-
lished by our group in an evaluation of whether these
parameters indicate the clinical NPSLE status before
and after treatment and whether they are related to dif-
ferent NPSLE syndromes.
PATIENTS AND METHODS
Data source and population. All patients were admit-
ted for a 1-day period to the Leiden University Medical Cen-
ter. Our hospital serves as a national referral center for
NPSLE in The Netherlands. From September 1, 2007 through
March 31, 2012, a total of 183 patients suspected of having NP
involvement due to SLE were evaluated in the Leiden NPSLE
clinic. All patients underwent a standardized multidisciplinary
medical examination, as well as extensive neuropsychologic
testing, serologic assessment, and brain MRI. Patients were
classified according to the ACR 1982 revised criteria for SLE
(20,21). SLE disease activity was determined with the use of
the Systemic Lupus Erythematosus Disease Activity Index
2000 (SLEDAI-2K) (22). Irreversible damage due to SLE was
assessed with the Systemic Lupus International Collaborating
Clinics (SLICC)/ACR damage index (SDI) (23). The
SLEDAI-2K and SDI values were calculated both with and
without NP manifestations. Soon after evaluation, a consensus
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meeting took place. Further descriptions of the multidiscipli-
nary evaluation and laboratory examination are available else-
where (6,24).
All patients were closely monitored by the referring
physician and reevaluated by our group 6–18 months after the
first visit. Twenty SLE patients without NP symptoms and 36
age-matched healthy control subjects were also included in
this study. Patients over the age of 70 years were excluded.
Written informed consent was obtained from all patients. The
study was approved by the local medical ethics committee and
was carried out in compliance with the Declaration of Helsinki.
NPSLE subgroups. Diagnosis of NPSLE was made
by multidisciplinary consensus, and NP diagnoses were classi-
fied according to the ACR 1999 definitions of NPSLE
(3,20,21). More than 1 NP diagnosis per patient was possible.
We included in the NPSLE group only patients with at least
1 NPSLE syndrome involving the CNS. For each NPSLE
patient, a suspected pathogenic mechanism was also assessed.
We differentiated between inflammatory and ischemic
NPSLE, as discussed above. Both inflammatory and ischemic
phenotypes could coexist in the same patient. Changes in the
clinical NP status between the first and second visits were
assessed 6–18 months later and were classified as worse, stable,
or improved by multidisciplinary consensus (rheumatology [C-
MC, TWH, and GMS-B], neurology [NDK], psychiatry
[NJrdw], neuropsychology [HAM], and neuroimaging [BE and
MAVB]). In an important subgroup of SLE patients, the NP
symptoms were explained by another diagnosis. These SLE
patients with NP symptoms unrelated to SLE (non–SLE-related
NP) were considered a different subgroup. During follow-up,
none of the patients in the 2 groups with NP symptoms (n5 64)
developed new NP symptoms.
MRI protocol and scoring. All patients underwent
brain MRI according to the same protocol and using the same
scanner. All scans were performed on a 3T MRI scanner
(Achieva; Philips Healthcare). The protocol included high-
resolution T1-weighted, T2-weighted, and fluid-attenuated
inversion recovery sequences, followed by a T1-weighted
sequence obtained after intravenous administration of gado-
linium contrast agent. An experienced radiologist (BE) who
was blinded with regard to the clinical status of the patients
visually examined all MRIs for the presence of abnormalities
and for their suitability for MTI. To avoid any influence of
ischemic areas due to thromboembolic processes on our
results, we excluded patients with radiologic evidence of other-
than-incidental small (.5 mm) infarctions and moderate atro-
phy, as measured by the Pasquier scale (grade .2; widened
sulci, volume loss of the gyri). This scale, the most frequently
used visual rating scale for cortical atrophy (scored on a 0–3
scale), considers the volume of the gyri and width of the sulci
(25). The differential diagnosis of ischemic NPSLE without
macroscopic abnormalities on MRI included cerebrovascular
disease as well as demyelinating syndromes and complex
migraines.
MTI protocol. MTI scans were performed using the
same acquisition parameters for all NPSLE, non–SLE-related
NP, and SLE patients and healthy control subjects. MTR data
were obtained by using a 3-dimensional gradient-echo
sequence with a repetition time/echo time of 100/11 msec and
a low flip angle of 98, to achieve minimal T1 weighting. A total
of 20 slices of 7.2 mm in thickness were acquired in an axial
orientation, with a field of view of 224 3 180 3 144 mm3 and
an acquisition matrix of 224 3 210 (voxel size 0.875 3
0.875 mm2). To reduce acquisition time, segmented echo-
planar imaging (EPI) was applied, with 13 k-space profiles col-
lected per excitation pulse (EPI factor 13). Two consecutive
sets of axial images were acquired. The first set was performed
in combination with a radiofrequency saturation pulse and the
second without. Total scanning time was 1 minute 8.3 seconds.
Image processing. For postprocessing of magnetiza-
tion transfer images, all images were transferred to an offline
Linux workstation. All MTR processing steps were performed
using software from the Oxford University Centre for Func-
tional Magnetic Resonance Imaging of the Brain (FMRIB)
Software Library (FSL) (26). MTR was defined as follows:
MTR5 M02Ms½ =M0ð Þ3 100
where M0 represents the signal intensity of voxels without sat-
uration, and Ms represents the signal intensity of voxels with
saturation.
Skull stripping was performed using FSL BET soft-
ware (27). A detailed description of the segmentation process
based on the T1-weighted image and the way in which the
resulting tissue masks were applied to the original MTR maps
to calculate the tissue MTR maps (WM and GM) is reported
in detail elsewhere (13). To avoid the partial-volume effect of
cerebrospinal fluid (CSF) at the tissue borders, the resulting
maps were eroded in-plane. From the remaining voxels, only
those for which the probability of belonging to WM .85%
and GM .80% were considered for the histogram analysis.
All parenchyma segmentation was based on hard binary seg-
mentations of GM and WM. All images were inspected visually
to confirm adequate extraction of intracranial data.
MTR histogram analysis. From the MTR maps, WM
and GM MTR histograms were created with 100 bins and a
bin size of 1. The first bin was excluded since it contains the
voxels with an intensity of zero. The remaining 99 bins were
taken into account for the subsequent calculations. MTR his-
tograms were normalized for intracranial volume by dividing
the number of voxels for each MTR value by the total number
of CSF, WM, and GM voxels. The corresponding peak height
(PH) and peak location were calculated for WM and GM
based on each normalized histogram using an in-house MatLab
code. Peak location is an indicator of which MTR value is
occurring more often. Peak height is a measure of the voxel
fraction found to have the MTR value of the peak location.
None of the WM or GM HPHs was used for clinical
considerations.
Statistical analysis. Statistical analysis included as
the primary dependent measures the HPHs from the segmented
WM and GM. Both were normally distributed. Equality of
variances in WM and GM HPHs between NPSLE patients,
non–SLE-related NP patients, SLE patients, and healthy con-
trols was assessed using Levene’s test. Between-group differ-
ences in WM and GM HPHs were evaluated using one-way
analysis of variance (pairwise comparisons). In the event of
unequal variances, appropriate adjustments in the pairwise
comparisons of the means were performed according to Tam-
hane’s procedure. Analysis of covariance was performed to
analyze the influence of disease duration, SLEDAI-2K, SDI,
smoking status, hypertension, and anticardiolipin antibodies
(aCL) on the between-group differences in mean peak height
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values. The association between NPSLE syndromes and HPH
values was assessed by independent t-test for every NPSLE
syndrome present in .5 patients, taking into account a possi-
ble inequality of variances. A paired samples t-test was per-
formed to test for significant mean differences in HPHs before
and after treatment of active NPSLE. Statistical analysis was
performed using SPSS version 20.0 software for Windows.
RESULTS
Patient selection and characterization. From
all patients who were evaluated, 135 (73.8%) fulfilled
the revised ACR criteria for SLE. In 59 of these patients
(43.7%), a diagnosis of CNS NPSLE was established at
the second visit. In the remaining patients, the NP symp-
toms were not directly attributable to SLE. After MRI
evaluation, a total of 33 patients with CNS NPSLE and
31 with non–SLE-related NP met the criteria for our
MTR study. The rest of the patients were excluded
because of the presence of abnormalities on convention-
al MRI. Table 1 shows the clinical characteristics and
autoantibody profiles of the study patients at the time of
the first MRI. The values for the SLEDAI-2K with and
Table 1. Characteristics of the study patients, by diagnostic group*
NPSLE
patients
(n5 33)
Non–SLE-related
NP patients
(n5 31)
SLE
patients
(n5 20)
Age, mean6 SD years 37.26 13.3 39.46 14.9 41.16 11.1
Sex, no. female/male 29/4 28/3 18/2
SLE disease duration, mean6 SD years 5.26 5.9 7.26 7.3 8.86 5.9
NP symptom duration, mean6 SD years 1.26 2.7 2.76 3.3 –
SLEDAI-2K, mean6 SD
Without NP symptoms 6.86 4.4 4.36 3.2† 2.76 2.4‡
With NP symptoms 13.66 5 4.36 3.2‡ 2.76 2.4‡
SDI, mean6SD
Without NP symptoms 1.46 1.2 16 1.1 1.26 1.2
With NP symptoms 2.26 1.4 1.26 1.1‡ 1.26 1.2†
ACR 1982 criteria for SLE, no. (%)
Malar rash 16 (48.5) 14 (45.2) 11 (55)
Discoid rash 2 (6.1) 6 (19.4) 5 (25)
Photosensitivity 10 (30.3) 15 (48.4) 11 (55)
Mucosal ulcers 08 (24.2) 9 (29) 12 (60)
Arthritis 25 (75.7) 20 (64.5) 18 (90)
Serositis 9 (27.3) 10 (32.2) 3 (15)
Renal disorder 9 (27.3) 9 (29) 4 (20)
Neurologic disorder 13 (39.4) 0 (0) 0 (0)
Hematologic disorder 17 (51.5) 14 (45.2) 15 (75)
Immunologic disorder 29 (87.9) 21 (67.7) 18 (90)
Positive ANA 31 (93.9) 30 (96.8) 20 (100)
Autoantibodies and complement, no. (%)
IgG aCL 08 (24.2) 5 (16.1) 2 (10)
IgM aCL 1 (3) 2 (6.5) 2 (10)
LAC 13 (39.4) 5 (16.1) 3 (15)
ANA 29 (87.9) 24 (77.4) 18 (90)
Anti-dsDNA 13 (39.4) 9 (29) 9 (45)
ENA 16 (48.5) 16 (51.6) 08 (40)
Anti-SSA 9 (27.3) 11 (35.5) 6 (30)
Anti-SSB 3 (9.1) 6 (19.4) 2 (10)
Anti-RNP 08 (24.2) 3 (9.7) 4 (20)
Anti-Sm 6 (18.2) 3 (9.7) 4 (20)
Low C1q 3 (9.1) 1 (3.2) 1 (5)
Low C3 13 (39.4) 10 (32.3) 3 (15)
Low C4 12 (36.4) 6 (19.4) 5 (25)
* Three groups of systemic lupus erythematosus (SLE) patients were studied: those with neuropsychia-
tric SLE (NPSLE), those with NP symptoms unrelated to the SLE (non–SLE-related NP), and those
with SLE without NP symptoms. A group of 36 healthy control subjects (32 women and 4 men; mean6
SD age 40.16 11.8 years) was also studied. SLEDAI-2K5SLE Disease Activity Index 2000;
SDI5 Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR)
Damage Index; ANA5 antinuclear antibody; aCL5 anticardiolipin antibody; LAC5 lupus anticoagu-
lant; anti-dsDNA5 anti–double-stranded DNA; ENA5 extractable nuclear antigen.
† P, 0.05 versus NPSLE patients.
‡ P, 0.001 versus NPSLE patients.
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without NP symptoms and for the SDI with NP symp-
toms were significantly higher in the NPSLE group. No
differences were found for the SDI values without NP
symptoms. Among the patients diagnosed as having
CNS NPSLE, 22 had inflammatory NPSLE and 11 had
ischemic NPSLE. Fifty-four different ACR NP syndromes
were established. Detailed clinical characteristics, includ-
ing ACR NPSLE syndromes and NPSLE phenotype, are
presented in Supplementary Table 1 (available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39653/abstract).
White and gray matter MTR-HPHs and NPSLE
diagnoses. The mean6SD values for the MTR-HPHs
in the white and gray matter are shown in Table 2. The
mean differences in the white and gray matter MTR-
HPHs between the diagnostic groups are shown in
Table 3. NPSLE patients with CNS involvement had sig-
nificantly lower WM MTR-HPHs than did the healthy
controls (P, 0.001) and the SLE patients (P5 0.001).
No differences were found between the NPSLE group
and the non–SLE-related NP group (P5 0.114). Patients
with non–SLE-related NP had significantly lower WM
MTR-HPHs than the healthy controls (P, 0.001). After
adjustment according to the Tamhane procedure, no sta-
tistically significant differences between non–SLE-related
NP patients and SLE patients were found (P5 0.063).
Moreover, no statistically significant differences in WM
values between the SLE patients and healthy controls
were found. We did not find any significant differences in
the mean GM MTR-HPHs between the various sub-
groups. Analyses controlling for differences attributable
to disease duration, SLEDAI-2K, SDI, smoking status,
hypertension, and aCL did not reveal any significant
influence on the previous findings. Figure 1 shows the
mean WMMTR histograms after correction for intracra-
nial volume in the NPSLE, non–SLE-related NP, and
SLE patients as well as in the healthy controls.
Table 2. White matter and gray matter MTR-HPHs measured in
the study groups*
No. of
subjects
MTR-HPH, mean6SD
White matter Gray matter
Healthy controls 36 43.376 5.11 10.016 2.51
SLE 20 42.746 6.22 10.026 1.92
Non–SLE-related NP 31 38.356 4.64 9.816 3.68
NPSLE 33 34.626 7.55 8.566 3.31
Phenotype
Inflammatory NPSLE 22 32.226 7.76 7.716 3.25
Ischemic NPSLE 11 39.426 4.21 10.256 2.85
* Peak height values were multiplied by 10,000 for readability. See Table
1 for definitions of the study groups. MTR-HPH5 magnetization trans-
fer ratio histogram peak height.
Table 3. Mean differences in white matter and gray matter MTR-HPHs between the study groups after the Tam-
hane procedure, by NPSLE diagnosis and NPSLE phenotype*
White matter peak height Gray matter peak height
Difference P (95% CI) Difference P (95% CI)
NPSLE diagnostic groups
NPSLE versus
Healthy controls 28.74 0.000 (213.02, 24.47)† 21.45 0.247 (23.39, 0.48)
SLE patients 28.12 0.001 (213.38, 22.85)‡ 21.64 0.150 (23.61, 0.32)
Non–SLE-related NP patients 23.73 0.114 (27.98, 0.51) 21.24 0.654 (23.63, 1.14)
Non–SLE-related NP versus
Healthy controls 25.01 0.000 (28.24, 21.77)† 20.21 1.000 (22.35, 1.93)
SLE patients 24.39 0.063 (28.93, 0.16) 20.39 0.997 (22.56, 1.76)
SLE versus
Healthy controls 20.62 0.999 (25.19, 3.94) 0.19 1.000 (21.45, 1.84)
NPSLE phenotype groups
Inflammatory NPSLE versus
Healthy controls 211.14 0.000 (216.74, 25.54)† 22.29 0.073 (24.71, 0.12)
SLE patients 210.52 0.000 (216.93, 24.11)† 22.48 0.044 (24.93, 20.04)‡
Non–SLE-related NP patients 26.13 0.023 (211.71, 20.55)‡ 22.09 0.296 (24.91, 0.72)
Ischemic NPSLE patients 27.19 0.001 (211.36, 23.02)‡ 22.53 0.276 (25.96, 0.89)
Ischemic NPSLE versus
Healthy controls 23.94 0.165 (28.75, 0.86) 0.24 1.000 (22.89, 3.37)
SLE patients 23.32 0.607 (29.05, 2.41) 0.47 1.000 (23.11, 3.19)
Non–SLE-related NP patients 1.06 0.999 (23.73, 5.86) 0.44 1.000 (22.92, 3.81)
* See Table 1 for definitions of the study groups. MTR-HPH5magnetization transfer ratio histogram peak height;
95% CI5 95% confidence interval.
† P, 0.001.
‡ P, 0.05.
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White and gray matter MTR peak heights and
NPSLE phenotypes. Table 3 shows the mean differ-
ences in white and gray matter MTR-HTPs in the
NPSLE phenotype groups. Patients with inflammatory
NPSLE had significantly lower WM MTR-HPHs as
compared with the healthy controls (P, 0.001), the
SLE patients (P, 0.001), and the non–SLE-related NP
patients (P5 0.023). Moreover, patients with inflamma-
tory NPSLE had significantly lower WMMTR-HPHs as
compared with patients with ischemic NPSLE
(P5 0.001). No statistically significant differences were
found for WM values when we compared ischemic
NPSLE patients with healthy controls, non–SLE-related
NP patients, or SLE patients. Patients with inflammato-
ry NPSLE also had significantly lower GM MTR-HPHs
as compared with the SLE patients (P5 0.044), but we
found no other differences as compared with the other
subgroups. We did not find any statistically significant
differences for the GM values when ischemic NPSLE
patients were compared with the healthy controls, the
non–SLE-related NP patients, and the SLE patients.
Analyses controlling for differences attributable to dis-
ease duration, SLEDAI-2K, SDI, smoking status, hyper-
tension, and aCL did not reveal any significant influence
on the previous findings. WM MTR histograms in the 5
study groups are shown in Figure 1B.
White and gray matter MTR peak heights and
NPSLE syndromes. Independent t-test analyses were
performed for every NPSLE syndrome present in .5
patients. Patients with cerebrovascular disease (n5 11),
psychosis (n5 8), headache (n5 8), seizure (n5 5),
cognitive disorder (n5 9), and mood disorder (n5 10)
were analyzed individually. Psychosis was associated
with lower WM (P 5 0.033) and GM (P 5 0.029) MTR-
HPHs. We also found an association between lower
WM MTR-HPHs and cognitive disorder (P 5 0.047) as
well as mood disorder (P 5 0.025). We did not find any
association between the GM MTR-HPHs and either
cognitive disorder or mood disorder. Cerebrovascular
disease was also associated with higher WM MTR-
HPHs (P 5 0.006). We found no associations between
MTR-HPHs and headache or seizure.
White matter MTR peak heights and clinical
changes. Of the 20 NPSLE patients considered to have
active CNS disease during the first visit, 11 were classi-
fied as improved after treatment, 7 as stable, and 2 as
worse. The mean6 SD WM MTR-HPHs in all patients
at the first visit was 31.516 7.83, and at the follow-up
visit, this value had increased to 39.076 6.56. Figure 2
shows WM MTR histograms before and after treatment
(after correction for intracranial volume). In all NPSLE
patients with clinical improvement, the mean WM
MTR-HPH increased by 9.816 5.94 (range 5.81 to 13.81)
(P, 0.000). The mean6 SD difference in WM MTR-
HPHs in patients classified as stable at the second visit
was 2.486 4.65 (range 1.81–6.79) (P5 0.207). In the
Figure 1. Average white matter magnetization transfer ratio (MTR) histograms. Mean MTR histograms after correction for intracranial volume
are shown in A, patients with neuropsychiatric systemic lupus erythematosus (NPSLE), patients with NP symptoms unrelated to the underlying
SLE (non–SLE-related NP), SLE patients without NP symptoms, and healthy control (HC) subjects, as well as in B, patients with inflammatory
NPSLE, ischemic NPSLE, non–SLE-related NP, SLE patients without NP symptoms, and healthy control subjects. pu5percentage units.
Figure 2. Average white matter magnetization transfer ratio (MTR)
histograms after correction for intracranial volume are shown in
patients with active neuropsychiatric systemic lupus erythematosus
(NPSLE) at baseline (first visit) and in the same NPSLE patients
after treatment (second visit). Baseline MTR histograms for SLE
patients without NP symptoms and for healthy control (HC) subjects
are included for comparison. pu5 percentage units.
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2 patients whose condition worsened, a decrease in the
WM MTR-HPH between the first and second MRI
was observed: 210.326 0.41 (range 214.01 to 26.63)
(P5 0.018).
DISCUSSION
This study is the first to show that NPSLE
patients with an inflammatory phenotype have signifi-
cantly lower WM MTR-HPHs than do ischemic
NPSLE, non–SLE-related NP, or SLE patients or
healthy controls. We also found that WM MTR-HPH is
sensitive to clinical changes. Based on these findings, we
propose that the WM MTR-HPH is a potentially valu-
able tool for use in the diagnosis and follow-up of
inflammatory NPSLE.
Inflammatory NPSLE is thought to reflect neu-
ronal dysfunction mediated by inflammatory factors,
autoantibodies, and increased SLE disease activity.
Apart from global and localized ischemic changes, histo-
pathologic data in NPSLE show parenchymal edema,
glial hyperplasia, and diffuse neuronal/axonal loss (7). It
has been hypothesized that MTR changes are associated
with all of these findings and may thus also explain our
results (13,18). In multiple sclerosis, MTR abnormali-
ties have been described as a useful tool for assessing
disease burden and evaluating disease progression (28).
However, demyelination is not a primary phenomenon
in NPSLE, and other mechanisms may play a more
important role in these MTR changes (8). The fact that
the WM MTR-HPHs in patients with ischemic NPSLE,
mainly seen in those with cerebrovascular symptoms,
were lower than those in the healthy controls and signif-
icantly higher than those in patients with inflammatory
NPSLE may suggest cumulative chronic damage of the
brain, as reported previously (13,16). Furthermore,
mean MTR-HPHs at the second visit were, on average,
closer to those in ischemic NPSLE patients, probably
reflecting residual effects or WM-specific and irrevers-
ible changes in patients with past inflammatory NPSLE.
To our knowledge, this is the first study in which
prospective follow-up was performed in order to avoid
misclassification of the putative cause of NP symptoms
in SLE. This standardized assessment is the most appro-
priate reference standard for diagnosis so far (29). In
addition, we were able to include patients with CNS
involvement without remarkable abnormalities on MRI.
These well-defined data are an additional benefit of our
study. This study also reproduced some data previously
published by our group.
We found that NPSLE patients and non–SLE-
related NP patients have, on average, significantly lower
WM MTR-HPHs than do healthy controls. Further-
more, the WMMTR-HPHs in NPSLE patients were sig-
nificantly lower on average than those in SLE patients,
but no differences were found between SLE patients and
non–SLE-related NP patients. The usefulness of whole-
brain parenchyma or segmented tissue MTR-HPHs for
the differentiation of SLE patients with NP symptoms
has previously been reported (13–15,17,30,31). Studies
based on other quantitative radiologic techniques, such
as proton magnetic resonance spectroscopy and diffu-
sion tensor imaging, have demonstrated a loss of WM
integrity in SLE patients and non–SLE-related NP
patients as compared with healthy controls (13,32–34).
Using MTI, we found no differences between SLE
patients and healthy controls, which may suggest that
each technique identifies different aspects of the
microstructural changes in the brains of SLE and
NPSLE patients. As previously reported, no differ-
ences between NPSLE patients and non–SLE-related
NP patients were found, probably because the NPSLE
group included both ischemic and inflammatory
NPSLE subgroups (13).
There may be 2 possible explanations for the
lower WM MTR-HPH values in the non–SLE-related
NP patients. Despite multidisciplinary assessment, we
still might have misclassified some NPSLE patients as
having non–SLE-related NP. Additionally, the non–
SLE-related NP group included a broad spectrum of
active neurologic and psychiatric disorders, which may
have influenced the MTR results, as lower MTR values
have been previously reported in patients with behavior-
al, psychotic, and neurodegenerative disorders (35–37).
Cognitive dysfunction was associated with lower
WM MTR-HPHs, as previously observed in other stud-
ies (13,16). We also found an association between psy-
chosis and lower WM and GM MTR-HPHs, as well as
between mood disorder and WM MTR-HPHs. In con-
trast, cerebrovascular disease was related to higher WM
MTR-HPHs, and no associations for headache or sei-
zure were noted. Cognitive dysfunction, psychosis, and
mood disorder may share a similar pathogenic pathway
as compared with other syndromes. However, these
results may be related to the prevalence of certain syn-
dromes and their activity at the time of MRI as well as
to the heterogeneity of NPSLE. As mentioned above,
nonspecific microstructural changes of the brain tissue
as measured by MTR have been found in several brain
regions in patients with cognitive impairment, psychosis,
and mood disorder (35–37).
As demonstrated previously (18), we have seen
how brain involvement in patients with active NPSLE
with unremarkable findings on MRI is partially reversible
USEFULNESS OF MTI IN IDENTIFYING INFLAMMATORY NPSLE 1951
when measuring WM MTR-HPHs. These values
decreased or increased in parallel with the clinical status
of the patients, as assessed by our multidisciplinary
group. It has been suggested that these changes may be
linked to the resolution or exacerbation of general
inflammatory changes of the brain (7,18). It is unclear
whether these MTR changes after treatment are associat-
ed with remyelination, as has been demonstrated in mul-
tiple sclerosis (18,38). Our data reinforce the idea that
MTI, especially the MTR histogram analysis, may be a
useful tool for evaluating disease progression and
response to therapy.
Our results also show a lower GM MTR-HPH in
patients with inflammatory NPSLE as compared with
those with SLE and a trend as compared with healthy
controls. The difference between NPSLE patients and
healthy controls was previously reported by Steens and
coworkers (17). The selective lowering of the GM
MTR-HPH in patients with inflammatory CNS NPSLE
without remarkable abnormalities on MRI may reveal
GM-specific changes. However, these data should be
viewed with caution, since several factors could affect
these results. The presence of cortical atrophy, especial-
ly focal, has been observed in NPSLE (8,9). Due to par-
tial volume effects, the voxels analyzed in the
parenchymal cortex contain a mixture of GM, WM, and
CSF. This may lead to a misclassification of those voxels
as GM and, subsequently, to decreased GM MTR-
HPHs. To avoid the effect of atrophy, we used the Pas-
quier scale for patient selection, as well as stringent
thresholds for GM parenchyma analysis to reduce par-
tial volume effects as much as possible without losing
the representation of the segmented tissue type.
We were not able to reproduce other data previ-
ously published by our group in studies of a smaller
number of patients. Steens and coworkers found an
association between certain MTR values (WM and GM
mean MTR and peak location) and positivity for IgM
aCL, suggesting that these antibodies may be associated
with diffuse brain involvement (17). This association
between MTR values and aCL status was not further
confirmed (13). We found no association between aCL
and HPHs. Previously, an association between certain
SLE criteria, such as arthritis and renal involvement,
and MTR-HPHs was observed (13). In the present
study, associations between HPHs and disease activity
(SLEDAI-2K) were not found. We believe that our pre-
vious data may show false-positive associations based on
the small sample size.
The main limitation of our study is the small num-
ber of patients per group and per syndrome. This is a gen-
erally recognized problem related to the low prevalence
and the high heterogeneity of NPSLE. We therefore can-
not draw definite conclusions concerning the relationship
between the MTR-HPH findings and NPSLE syndromes.
Furthermore, due to matters of referral, some of the
patients with inflammatory NPSLE were evaluated in the
NPSLE clinic once they had started the immunosuppres-
sive therapy. This may explain the higher variance in the
NPSLE group, and we believe that inflammatory NPSLE
would probably have shown lower values in comparison
with other groups if none of these patients had received
prior therapy.
A second limitation is that for research purposes,
we selected patients with unremarkable findings on
MRI, excluding a high proportion of patients to avoid
the influence of thromboembolic processes. Our data
can thus be extrapolated only to NPSLE patients with
unremarkable MRI findings, since the effect of the pres-
ence of infarcts and WM lesions on the MTR-HPHs val-
ues remains unknown. Another limitation of our study
is the possible misclassification of inflammatory NPSLE
based on a good response to therapy, whereas the clini-
cal response could have been the normal waxing and
waning of the disease course or due to their inclusion in
this group of nonspecific NPSLE syndromes (headache,
mood disorder, anxiety, and mild cognitive dysfunction).
However, such misclassification would lead to smaller
differences between groups, and the real differences
may therefore be even larger than we report here. A
final limitation is that due to the impaired clinical status
of some patients, we had to decrease the scanning time,
which subsequently affected the resolution, resulting in
partial volume effects, which may cause misclassification
of GM and WM voxels.
In conclusion, this is the first study to demon-
strate that WM MTR-HPHs might provide evidence of
the presence of inflammatory NPSLE. This study also
confirmed the usefulness of this technique in the detec-
tion of cerebral changes in NPSLE and in the assess-
ment of clinical changes after treatment of patients with
active disease. Moreover, a lower WM MTR-HPH was
associated with cognitive dysfunction, mood disorder,
and psychosis. Further studies are required to fully
determine whether these data reflect the burden of SLE
on the brain or whether they represent the severity of
NP symptoms apart from the SLE. Our results are con-
sistent with previous data reported by our group, thus
broadening their significance. The findings of our study
illustrate the value of MTR-HPH analysis as a potential
radiologic biomarker that may help in the diagnostic
process and follow-up of patients with NPSLE and with
the monitoring of future treatment trials.
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